Pharmaceutical composition and method of treating hematologic malignancies
AssigneeIsm Biosciences LLC
InventorsMax Temnik, Victor Gurin, Sergey Gurin
Life of this patent
Estimating the term…
Abstract
A method for treating hematologic malignancies comprises administration of a composition inclusive of 64Zne(Asp) in a therapeutically effective amount. Such administration may be via intravenous injection and/or infusion and may be once a day or more than once a day. Other identified compounds may be bound to 64Zne replacing L-Aspartate (Asp), provided that the resulting molecular weight does not exceed 700 Da and the resulting compound nanoparticles are less than 50.5 nm in size. The composition is suitable for intravenous injection and/or infusion.
Claims3
A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64Zne(Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn, and wherein aspartate is replaced by one or more of quercetin, apigenin, genistein, kaempferol, and chrysin, wherein the resulting molecule size is below 700 Da.
A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of and wherein aspartate is replaced by one or more 64Zne(Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn, and wherein aspartate is replaced by one or more of curcumin, epigallocatechin gallate, or resveratrol, wherein the resulting molecule size is below 700 Da.
A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64Zne (Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64Zne is administered to patient, wherein the 64Zne is at least 90% 64Zn, and wherein the composition includes a carrier selected from an ionophore, metallophore, polymeric micelle, metal organic framework, liposome, or a loaded platelet.
Dependencies are inferred from the claim text.